Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134154 | 1.00 | MEN1 (0.40) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL2476608 | 1.00 | MEN1 (0.40) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL2478679 | 0.83 | APLNR (0.43) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL6858040 | 0.83 | APLNR (0.43) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL30848143 | 0.83 | APLNR (0.43) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL3708094 | 0.83 | APLNR (0.43) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL12179378 | 0.83 | GABRA1 (0.37) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL27899325 | 0.81 | PSEN1 (0.34) | MEN1KMT2ACES2CES1KCNH2 | |
| SCHEMBL28502722 | 0.79 | PDE2A (0.39) | PDE2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21985953 | 0.79 | CES2 (0.37) | CES2CES1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| CN-111925360-B | 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3630748-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20210284628-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| CN-102439010-A | Process for the production of fused, tricyclic sulfonamides | ELAN PHARM INC | 2012-05-02 | — | — | CN | disclosed |
| EP-2411388-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| CN-102307847-A | Indanyl compounds | DAIICHI SANKYO CO LTD | 2012-01-04 | — | — | CN | disclosed |
| CN-102307852-A | Cyclic amine compounds | DAIICHI SANKYO CO LTD | 2012-01-04 | — | — | CN | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| WO-2010111418-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | MEN1 3179/4885KMT2A 3652/4885CES2 1161/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | MEN1 3612/4885KMT2A 2438/4885CES2 3827/4885 |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | CBR3, DRD4, SBDS | MEN1 3139/4885KMT2A 1209/4885CES2 545/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | MEN1 3837/4885KMT2A 2627/4885CES2 4522/4885 |
| US-20210284628-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | MEN1 3601/4885KMT2A 2312/4885CES2 2722/4885 |
| US-11649224-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | MEN1 3601/4885KMT2A 2312/4885CES2 2722/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | MEN1 3837/4885KMT2A 2627/4885CES2 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.